vs
GRIFFON CORP（GFF）とRevvity（RVTY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Revvityの直近四半期売上が大きい（$772.1M vs $649.1M、GRIFFON CORPの約1.2倍）。Revvityの純利益率が高く（12.7% vs 9.9%、差は2.8%）。Revvityの前年同期比売上増加率が高い（5.9% vs 2.6%）。Revvityの直近四半期フリーキャッシュフローが多い（$161.8M vs $99.3M）。過去8四半期でRevvityの売上複合成長率が高い（9.0% vs -1.8%）
グリフォン・コーポレーションはニューヨークに本社を置く多国籍複合企業で、多角化経営の持株会社として事業を展開しています。傘下にAmes True Temper、ClosetMaid、クロペイ建築製品、CornellCooksonの4つの子会社を持ち、1961年からニューヨーク証券取引所に上場しており、S&Pスモールキャップ600、S&Pコンポジット1500、ラッセル2000の各指数の構成銘柄です。
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
GFF vs RVTY — 直接比較
損益計算書 — Q1 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $649.1M | $772.1M |
| 純利益 | $64.4M | $98.4M |
| 粗利率 | 41.1% | — |
| 営業利益率 | 17.5% | 14.5% |
| 純利益率 | 9.9% | 12.7% |
| 売上前年比 | 2.6% | 5.9% |
| 純利益前年比 | -9.1% | 3.9% |
| EPS（希薄化後） | $1.41 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $649.1M | $772.1M | ||
| Q3 25 | $662.2M | $698.9M | ||
| Q2 25 | $613.6M | $720.3M | ||
| Q1 25 | $611.7M | $664.8M | ||
| Q4 24 | $632.4M | $729.4M | ||
| Q3 24 | $659.7M | $684.0M | ||
| Q2 24 | $647.8M | $691.7M | ||
| Q1 24 | $672.9M | $649.9M |
| Q4 25 | $64.4M | $98.4M | ||
| Q3 25 | $43.6M | $46.7M | ||
| Q2 25 | $-120.1M | $53.9M | ||
| Q1 25 | $56.8M | $42.2M | ||
| Q4 24 | $70.9M | $94.6M | ||
| Q3 24 | $62.5M | $94.4M | ||
| Q2 24 | $41.1M | $55.4M | ||
| Q1 24 | $64.1M | $26.0M |
| Q4 25 | 41.1% | — | ||
| Q3 25 | 41.7% | 53.6% | ||
| Q2 25 | 43.2% | 54.5% | ||
| Q1 25 | 41.2% | 56.5% | ||
| Q4 24 | 41.8% | — | ||
| Q3 24 | 39.9% | 56.3% | ||
| Q2 24 | 38.5% | 55.7% | ||
| Q1 24 | 40.2% | 54.6% |
| Q4 25 | 17.5% | 14.5% | ||
| Q3 25 | 18.0% | 11.7% | ||
| Q2 25 | -20.5% | 12.6% | ||
| Q1 25 | 16.5% | 10.9% | ||
| Q4 24 | 17.7% | 16.3% | ||
| Q3 24 | 16.9% | 14.3% | ||
| Q2 24 | 13.8% | 12.4% | ||
| Q1 24 | 16.9% | 6.8% |
| Q4 25 | 9.9% | 12.7% | ||
| Q3 25 | 6.6% | 6.7% | ||
| Q2 25 | -19.6% | 7.5% | ||
| Q1 25 | 9.3% | 6.4% | ||
| Q4 24 | 11.2% | 13.0% | ||
| Q3 24 | 9.5% | 13.8% | ||
| Q2 24 | 6.3% | 8.0% | ||
| Q1 24 | 9.5% | 4.0% |
| Q4 25 | $1.41 | $0.86 | ||
| Q3 25 | $1.04 | $0.40 | ||
| Q2 25 | $-2.65 | $0.46 | ||
| Q1 25 | $1.21 | $0.35 | ||
| Q4 24 | $1.49 | $0.77 | ||
| Q3 24 | $1.29 | $0.77 | ||
| Q2 24 | $0.84 | $0.45 | ||
| Q1 24 | $1.28 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $95.3M | $919.9M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $108.9M | $7.3B |
| 総資産 | $2.1B | $12.2B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $95.3M | $919.9M | ||
| Q3 25 | $99.0M | $931.4M | ||
| Q2 25 | $107.3M | $991.8M | ||
| Q1 25 | $127.8M | $1.1B | ||
| Q4 24 | $152.0M | $1.2B | ||
| Q3 24 | $114.4M | $1.2B | ||
| Q2 24 | $133.5M | $2.0B | ||
| Q1 24 | $123.0M | $1.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.6B | — |
| Q4 25 | $108.9M | $7.3B | ||
| Q3 25 | $74.0M | $7.4B | ||
| Q2 25 | $63.9M | $7.6B | ||
| Q1 25 | $214.7M | $7.6B | ||
| Q4 24 | $227.8M | $7.7B | ||
| Q3 24 | $224.9M | $7.9B | ||
| Q2 24 | $223.5M | $7.9B | ||
| Q1 24 | $202.2M | $7.8B |
| Q4 25 | $2.1B | $12.2B | ||
| Q3 25 | $2.1B | $12.1B | ||
| Q2 25 | $2.1B | $12.4B | ||
| Q1 25 | $2.3B | $12.4B | ||
| Q4 24 | $2.3B | $12.4B | ||
| Q3 24 | $2.4B | $12.8B | ||
| Q2 24 | $2.4B | $13.4B | ||
| Q1 24 | $2.4B | $13.4B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 22.71× | — | ||
| Q1 25 | 7.16× | — | ||
| Q4 24 | 6.48× | — | ||
| Q3 24 | 6.78× | — | ||
| Q2 24 | 6.74× | — | ||
| Q1 24 | 7.84× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $107.0M | $182.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $99.3M | $161.8M |
| FCFマージンFCF / 売上 | 15.3% | 21.0% |
| 設備投資強度設備投資 / 売上 | 1.2% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 1.66× | 1.85× |
| 直近12ヶ月FCF直近4四半期 | $278.9M | $509.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $107.0M | $182.0M | ||
| Q3 25 | $75.0M | $138.5M | ||
| Q2 25 | $123.1M | $134.3M | ||
| Q1 25 | $16.5M | $128.2M | ||
| Q4 24 | $142.9M | $174.2M | ||
| Q3 24 | $72.1M | $147.9M | ||
| Q2 24 | $122.1M | $158.6M | ||
| Q1 24 | $39.8M | $147.6M |
| Q4 25 | $99.3M | $161.8M | ||
| Q3 25 | $62.4M | $120.0M | ||
| Q2 25 | $114.4M | $115.5M | ||
| Q1 25 | $2.8M | $112.2M | ||
| Q4 24 | $125.5M | $149.8M | ||
| Q3 24 | $51.6M | $125.6M | ||
| Q2 24 | $107.5M | $136.6M | ||
| Q1 24 | $20.8M | $129.7M |
| Q4 25 | 15.3% | 21.0% | ||
| Q3 25 | 9.4% | 17.2% | ||
| Q2 25 | 18.6% | 16.0% | ||
| Q1 25 | 0.5% | 16.9% | ||
| Q4 24 | 19.8% | 20.5% | ||
| Q3 24 | 7.8% | 18.4% | ||
| Q2 24 | 16.6% | 19.7% | ||
| Q1 24 | 3.1% | 20.0% |
| Q4 25 | 1.2% | 2.6% | ||
| Q3 25 | 1.9% | 2.6% | ||
| Q2 25 | 1.4% | 2.6% | ||
| Q1 25 | 2.2% | 2.4% | ||
| Q4 24 | 2.8% | 3.4% | ||
| Q3 24 | 3.1% | 3.3% | ||
| Q2 24 | 2.2% | 3.2% | ||
| Q1 24 | 2.8% | 2.7% |
| Q4 25 | 1.66× | 1.85× | ||
| Q3 25 | 1.72× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | 0.29× | 3.03× | ||
| Q4 24 | 2.02× | 1.84× | ||
| Q3 24 | 1.15× | 1.57× | ||
| Q2 24 | 2.97× | 2.87× | ||
| Q1 24 | 0.62× | 5.67× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
GFF
| Consumer And Professional Products | $241.1M | 37% |
| Residential Repairand Remodel | $202.1M | 31% |
| International Excluding North America | $97.8M | 15% |
| Retail | $47.3M | 7% |
| Residential New Construction | $32.5M | 5% |
| Other | $14.2M | 2% |
| Industrial | $14.1M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
